Literature DB >> 27738827

Prognostic Impact of Node-Spreading Pattern in Surgically Treated Small-Cell Lung Cancer: A Multicentric Analysis.

Giovanni Leuzzi1, Filippo Lococo2, Gabriele Alessandrini3, Isabella Sperduti4, Lorenzo Spaggiari5, Federico Venuta6, Erino A Rendina7, Pierluigi M Granone8, Cristian Rapicetta9, Piero Zannini10, Gaetano Di Rienzo11, Maurizio Nicolosi12, Francesco Facciolo3.   

Abstract

OBJECTIVE: Although surgery in selected small-cell lung cancer (SCLC) patients has been proposed as a part of multimodality therapy, so far, the prognostic impact of node-spreading pattern has not been fully elucidated. To investigate this issue, a retrospective analysis was performed.
METHODS: From 01/1996 to 12/2012, clinico-pathological, surgical, and oncological features were retrospectively reviewed in a multicentric cohort of 154 surgically treated SCLC patients. A multivariate Cox proportional hazard model was developed using stepwise regression, in order to identify independent outcome predictors. Overall (OS), cancer-specific (CSS), and Relapse-free survival (RFS) were calculated by Kaplan-Meier method.
RESULTS: Overall, median OS, CSS, and RFS were 29 (95 % CI 18-39), 48 (95 % CI 19-78), and 22 (95 % CI 17-27) months, respectively. Lymphadenectomy was performed in 140 (90.9 %) patients (median number of harvested nodes: 11.5). Sixty-seven (47.9 %) pN0-cases experienced the best long-term survival (CSS: 71, RFS: 62 months; p < 0.0001). Among node-positive patients, no prognostic differences were found between pN1 and pN2 involvement (CSS: 22 vs. 15, and RFS: 14 vs. 10 months, respectively; p = 0.99). By splitting node-positive SCLC according to concurrent N1-invasion, N0N2-patients showed a worse CSS compared to those cases with combined N1N2-involvement (N0N2: 8 months vs. N1N2: 22 months; p = 0.04). On the other hand, the number of metastatic stations (p = 0.80) and the specific node-level (p = 0.85) did not affect CSS. At multivariate analysis, pN+ (HR: 3.05, 95 % CI 1.21-7.67, p = 0.02) and ratio between metastatic and resected lymph-nodes (RL, HR: 1.02, 95 % CI 1.00-1.04, p = 0.03) were independent predictors of CSS. Moreover, node-positive patients (HR: 3.60, 95 % CI 1.95-6.63, p < 0.0001) with tumor size ≥5 cm (HR: 1.85, 95 % CI 0.88-3.88, p = 0.10) experienced a worse RFS.
CONCLUSIONS: In selected surgically treated SCLC, the long-term survival may be stratified according to the node-spreading pattern.

Entities:  

Keywords:  Lymphadenectomy; Multimodality therapy; Node-spreading pattern; Ratio; Small-cell lung cancer; Surgery

Mesh:

Year:  2016        PMID: 27738827     DOI: 10.1007/s00408-016-9954-4

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  20 in total

1.  Results of preoperative mediastinoscopy for small cell lung cancer.

Authors:  M Inoue; K Nakagawa; K Fujiwara; K Fukuhara; T Yasumitsu
Journal:  Ann Thorac Surg       Date:  2000-11       Impact factor: 4.330

2.  A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer.

Authors:  Andrzej Badzio; Krzysztof Kurowski; Hanna Karnicka-Mlodkowska; Jacek Jassem
Journal:  Eur J Cardiothorac Surg       Date:  2004-07       Impact factor: 4.191

3.  Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer.

Authors:  N Hara; M Ohta; Y Ichinose; A Motohiro; T Kuda; H Asoh; M Kawasaki
Journal:  J Surg Oncol       Date:  1991-05       Impact factor: 3.454

4.  Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base.

Authors:  Susan E Combs; Jacquelyn G Hancock; Daniel J Boffa; Roy H Decker; Frank C Detterbeck; Anthony W Kim
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

5.  Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up.

Authors:  W Fox; J G Scadding
Journal:  Lancet       Date:  1973-07-14       Impact factor: 79.321

6.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

Authors:  Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  Lymph node staging by endobronchial ultrasound-guided transbronchial needle aspiration in patients with small cell lung cancer.

Authors:  Hironobu Wada; Takahiro Nakajima; Kazuhiro Yasufuku; Taiki Fujiwara; Shigetoshi Yoshida; Makoto Suzuki; Kiyoshi Shibuya; Kenzo Hiroshima; Yukio Nakatani; Ichiro Yoshino
Journal:  Ann Thorac Surg       Date:  2010-07       Impact factor: 4.330

8.  The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.

Authors:  Eric Vallières; Frances A Shepherd; John Crowley; Paul Van Houtte; Pieter E Postmus; Desmond Carney; Kari Chansky; Zeba Shaikh; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609

9.  A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy.

Authors:  T Lad; S Piantadosi; P Thomas; D Payne; J Ruckdeschel; G Giaccone
Journal:  Chest       Date:  1994-12       Impact factor: 9.410

10.  Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung.

Authors:  F A Shepherd; W K Evans; R Feld; V Young; G A Patterson; R Ginsberg; E Johansen
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

View more
  2 in total

1.  Role of surgery in patients with early stage small-cell lung cancer.

Authors:  Aimei Peng; Guoshu Li; Mengting Xiong; Shuanshuan Xie; Changhui Wang
Journal:  Cancer Manag Res       Date:  2019-07-26       Impact factor: 3.989

2.  Development and validation of a prognostic model of resectable small-cell lung cancer: a large population-based cohort study and external validation.

Authors:  Yu Wang; Zhaofei Pang; Xiaowei Chen; Tao Yan; Jichang Liu; Jiajun Du
Journal:  J Transl Med       Date:  2020-06-15       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.